Teva Branded Pharmaceutical Products R&D LLC et al v. Amneal Pharmaceuticals of New York, LLC et al

Docket No.
2:23-cv-20964
District Court
New Jersey

Goal

  • Block infringement of a patent

Issues

Case History

Why this Matters:

The plaintiffs argue that defendants infringed several of their patents, and defendants counter that plaintiffs improperly listed certain patents in the Orange Book to maintain exclusivity and block other generics from entering the market in violation of federal patent and antitrust law. Patent abuses can distort the market for prescription drugs and drive up prices for consumers.

Potential Impact:

Improper patent listings in the Orange Book can undermine fair competition and prohibit or delay consumers from accessing lower-cost generic drugs.

News And Analysis (1)

58 Major Filings

View More

Related Litigation

Current Status

Case dismissed

Legal Issues

Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act)

Amicus Briefs for Defendant(s)

FTC

Topic(s)

Orange Book Patent Listings

Date Filed
October 6, 2023
Case Type
Civil
Court Type
District Court
Court
New Jersey
Judge
Chesler, Stanley R. Appointed By: George W. Bush
Plaintiff(s)
Teva Branded Pharmaceutical Products, R&D LLC; Norton (Waterford) LTD; Teva Pharmaceuticals USA, Inc.
Lead Counsel For Plaintiff(s)
Liza M. Walsh - Walsh Pizzi O'Reilly Falanga LLP
Defendant(s)
Amneal Pharmaceuticals of New York, LLC; Amneal Ireland Limited; Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals Inc.
Lead Counsel for Defendant(s)
Stone Conroy LLC